Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis

Abstract

Ibrutinib is a novel drug used in haematological malignancies. Its use is associated with an increased risk of atrial fibrillation (AF), which, in turn, exposes patients to embolic risk, including stroke. Reducing this risk requires anticoagulant therapy which is a matter of concern in the context of the increased bleeding risk of patients with haematological malignancies. In this context the presence of thrombocytopenia related to haematological disorder, ibrutinib-anticoagulants and ibrutinib-platelets interactions contribute to the amplification of the problem. The correct assessment of the thrombosis vs. haemorrhage balance represents a significant challenge for the clinician.

Keywords

• ibrutinib
• atrial fibrillation
• anticoagulation
• thromboembolic prophylaxis
• haemorrhagic risk